<DOC>
	<DOCNO>NCT01900587</DOCNO>
	<brief_summary>The purpose study evaluate bio-equivalence tapentadol extended-release ( ER ) tamper-resistant formulation ( TRF ) tablet , current tapentadol ER , prolonged-release formulation 2 ( PR2 ) tablet , healthy participant .</brief_summary>
	<brief_title>A Pivotal Study Evaluate Bio-equivalence Tapentadol Extended-Release ( ER ) Tamper-resistant Formulation ( TRF ) Tablet Current Tapentadol ER Prolonged-release 2 ( PR2 ) Tablet</brief_title>
	<detailed_description>This single-dose , open-label ( medical research study participant researcher tell treatment participant receive , `` unblinded '' ) , single-centre , randomized ( like flip coin ; 50/50 chance receiving study treatment ) , 2-way crossover ( group participant receive two intervention particular order ) study single-dose tapentadol healthy participant fast condition . The study consist 3 part : Screening ( 2 21 day study commences ) , Open-label Treatment ( single-dose treatment Day 1 period separate wash-out period 7 14 day ) End study ( Day 3 treatment Period 2 ) . The duration participation study individual participant 5.5 week ( include Screening ) . Participants randomly assign one 2 treatment sequence group . Participants assign first treatment sequence receive tapentadol TRF 50 milligram ( mg ) tablet , washout period , participant receive tapentadol PR2 50-mg tablet . Participants assign second treatment sequence receive tapentadol PR2 50-mg tablet , washout period , participant receive tapentadol TRF 50-mg tablet . Bio-equivalence primarily evaluate pharmacokinetics parameter . Participant 's safety monitor throughout study .</detailed_description>
	<criteria>Participants deem healthy basis prestudy physical examination , medical history ( include smoke habit ) , 12lead electrocardiogram ( ECG ) , vital sign , clinical laboratory parameter ( serum chemistry , serology hematology ) perform within 21 day study drug administration Female participant must postmenopausal , surgically sterile , , childbearing potential/sexually active , practice effective method birth control throughout study . Women must negative serum beta human chorionic gonadotropin pregnancy test Screening Day 1 treatment period . Men must impregnate partner Participants body mass index ( BMI ) ( weight [ kilogram { kg } ] /height [ meter { } ^2 ] ) inbetween 20 28 kg/m^2 , inclusive , body weight less 50 kg Participants blood pressure 100 140 millimeter mercury ( mmHg ) systolic , inclusive , 50 90 mmHg diastolic Participants smoke 10 cigarette , 2 cigar , 2 pipe tobacco per day least 6 month first study drug administration Participants history seizure disorder epilepsy mild moderate traumatic brain injury , stroke , transient ischemic attack , brain neoplasm within 1 year screening , severe traumatic brain injury within 15 year screen , severe traumatic brain injury result ongoing squeal suggest transient change consciousness symptoms Participants history gastrointestinal disease affect absorption , gastric surgery history current significant medical illness include cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness Investigator considers exclude participant Participants receive experimental drug use experimental medical device within 30 day within period le 10 time drug 's halflife , whichever longer , first dose study drug schedule participate investigational drug study least 60 day completion study Participants positive test drug abuse , cannabinoids , alcohol , opiates , cocaine , amphetamine , benzodiazepine , barbiturate Screening Day 1 treatment period Participants donate blood blood product substantial loss blood ( great 500 milliliter ) within 2 month first administration study drug</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Bio-equivalence</keyword>
	<keyword>Tapentadol extend release</keyword>
	<keyword>Tamper-resistant formulation</keyword>
</DOC>